Completion of Nuvista Pharma acquisition

Published: 3-Apr-2018
Media Finance

Beximco Pharmaceuticals announced the company has completed the acquisition of a majority stake in Nuvista Pharma


Beximco Pharmaceuticals is manufacturer of generic pharmaceutical products and active pharmaceutical ingredients.

For the accquistion a total of 10,013,474 ordinary shares have been acquired from seven individual shareholders having an aggregate holding of 85.22% of the paid up capital of Nuvista.

Immediately after the acquisition, the board of Nuvista was reconstituted. The new five member board consists of four nominees from Beximco Pharma and one nominee representing the government shareholding in Nuvista.

  • Companies:
  • Beximco Pharmaceuticals
See more

You may also like

Ingredients

Beximco Pharma introduces first generic remdesivir for COVID-19

Read more
Beximco Pharma is donating remdesivir (Bemsivir) to the Bangladesh Government for supply only to Government hospitals

Trending Articles

  1. Merck attains $588m global license for PD-1/VEGF bispecific antibody from LaNova Medicines The bispecific antibody is designed for oncological indications and functions by inhibiting the PD-1/PD-L1 and the VEGF/VEGFR receptor signalling pathways
  2. Syncona launches early-stage drug development company, Slingshot Therapeutics The novel early-stage pharmaceutical company aims to collaborate with academic institutions to bring their findings to the clinic, with their first programme centring around inflammatory disease
  3. Ascend Advanced Therapies expands US footprint through Advanced BioScience Laboratories merger Ascend's collaboration with EW Healthcare partners will expand its reach in the US pharmaceutical market through capital investment and an uptick in GMP AAV manufacturing capacity
  4. AstraZeneca to stop production of Pulmicort pMDI Agreements with SkyePharma expected to be terminated
  5. LGC Standards acquires VHG Labs Further strengthening its position in the US

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Ingredients

Beximco Pharma introduces first generic remdesivir for COVID-19

Beximco Pharma is donating remdesivir (Bemsivir) to the Bangladesh Government for supply only to Government hospitals
Finance

Mylan chooses Beximco for exclusive antibody distribution in Bangladesh

Beximco Pharma has received the exclusive rights to launch Netherlands-based Mylan’s portfolio of key monoclonal antibodies in its headquarters of Bangladesh
Manufacturing

Acquisition of a majority stake in Nuvista Pharma

Beximco Pharmaceuticals, manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, announced it has acquired a majority stake in Nuvista Pharma, a leading pharma company in Bangladesh specialising in hormones and steroid drugs
Recruitment

Beximco Pharma forms joint venture with Malaysia-based BioCare Manufacturing

Beximco Pharmaceuticals, manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, announces the creation of a joint venture with BioCare Manufacturing
Finance

Merck attains $588m global license for PD-1/VEGF bispecific antibody from LaNova Medicines

The bispecific antibody is designed for oncological indications and functions by inhibiting the PD-1/PD-L1 and the VEGF/VEGFR receptor signalling pathways
Research & Development

Syncona launches early-stage drug development company, Slingshot Therapeutics

The novel early-stage pharmaceutical company aims to collaborate with academic institutions to bring their findings to the clinic, with their first programme centring around inflammatory disease
Manufacturing

Ascend Advanced Therapies expands US footprint through Advanced BioScience Laboratories merger

Ascend's collaboration with EW Healthcare partners will expand its reach in the US pharmaceutical market through capital investment and an uptick in GMP AAV manufacturing capacity
Subscribe now